2025 Q4 -tulosraportti
1 päivä sitten
‧24 min
Tarjoustasot
First North Sweden
Määrä
Osto
689
Myynti
Määrä
705
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 56 | - | - | ||
| 500 | - | - | ||
| 60 | - | - | ||
| 91 | - | - |
Ylin
35,5VWAP
Alin
34,3VaihtoMäärä
0,1 1 757
VWAP
Ylin
35,5Alin
34,3VaihtoMäärä
0,1 1 757
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 757 | 1 757 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 757 | 1 757 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·20.2.Ding Dong. FDA clears FluoGuides IND for FG001 🙌 https://storage.mfn.se/139b3b18-5b33-44a9-ad66-87fb5655209a/fda-clears-fluoguides-ind-for-fg001-in-high-grade-glioma-u-s-clinical-trial-remains-on-track.pdf
·19.2.The direct effect of FDA's new practice See the attached image . 1) One pivotal study may be enough → big gain The new FDA standard means that FluoGuide can potentially: 👉 Pursue one large registration study instead of two Consequences: • 🕒 Shorter path to market (1–3 years faster) • 💰 Lower development costs • 📉 Less capital raising / less dilution For a small Danish biotech company, this is very valuable. ⸻ 2) Endpoints fit well with the “one trial” model FluoGuide's type of product actually lends itself quite well to a one-study setup, because: • the effect can be measured directly during surgery (e.g.: more complete resections, fewer positive margins) • strong, objective endpoints can be obtained • results can often be seen quickly 👉 This is precisely the type of evidence FDA is willing to accept from one strong study. ⸻ 3) Less regulatory complexity than classic cancer medicine Compared to classic oncology treatment (such as with Curasight’s uTREAT): • FluoGuide does not have to prove overall survival benefit (OS) initially • the focus is on surgical outcome and visualization ➡️ This makes it more likely that FDA will accept one pivotal study. ⸻ 📊 What does this mean for the investment case? 💰 Capital requirements • One study instead of two can save very large amounts • increases the likelihood of reaching goals without massive capital raising 🤝 Partnering/M&A Big Pharma / MedTech may be more interested when: • there is a short path to approval • and low regulatory risk 👉 Increases the chance of a licensing agreement or acquisition earlier in the process 📈 Valuation The market usually rewards: • shorter timelines • higher probability of approval • lower cash burn ⸻ 🇪🇺 EU perspective Although approval in the EU goes via the European Medicines Agency: • The study will typically be designed so that it can be used for both FDA and EMA • EMA may require: • extra data • or an expanded cohort But: 👉 if FDA accepts one strong study, the probability of EU approval on the same data basis increases ⸻ ⚠️ What are still risks? Even with the new FDA line: • One study = binary risk • FDA may still require: • extra safety data • imaging quality data • If endpoints are not clear → they may still require an additional study ⸻ 🧾 Bottom line for FluoGuide 👉 The new FDA standard is very positive for FluoGuide In practice, this means: • faster path to market • lower capital requirements • better partnering opportunities • higher strategic value ➡️ Among Danish small-cap biotechs, FluoGuide is one of those that benefits most directly from this regulatory change.
·3 päivää sittenWhy does that result in lower capital requirements? I think it increases the capital requirement and know-how initially, and any potential savings can only be realized back-end upon success. All else being equal, it thus increases investors' risk appetite in the initial phase, and then there will be a payback if it succeeds. If it doesn't succeed, the loss will be greater because a large study was initiated earlier than otherwise. Why should that provide a better partner opportunity? It would rather imply that it increases the requirement to bring in a large partner as an investor, and thus one would have to sell out earlier in the journey, whereas one often sees a large return by taking phase 2 on one's own and waiting for a partnership until phase 3. Higher strategic value? Can that expression be translated into something that makes sense?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
1 päivä sitten
‧24 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·20.2.Ding Dong. FDA clears FluoGuides IND for FG001 🙌 https://storage.mfn.se/139b3b18-5b33-44a9-ad66-87fb5655209a/fda-clears-fluoguides-ind-for-fg001-in-high-grade-glioma-u-s-clinical-trial-remains-on-track.pdf
- ·19.2.The direct effect of FDA's new practice See the attached image . 1) One pivotal study may be enough → big gain The new FDA standard means that FluoGuide can potentially: 👉 Pursue one large registration study instead of two Consequences: • 🕒 Shorter path to market (1–3 years faster) • 💰 Lower development costs • 📉 Less capital raising / less dilution For a small Danish biotech company, this is very valuable. ⸻ 2) Endpoints fit well with the “one trial” model FluoGuide's type of product actually lends itself quite well to a one-study setup, because: • the effect can be measured directly during surgery (e.g.: more complete resections, fewer positive margins) • strong, objective endpoints can be obtained • results can often be seen quickly 👉 This is precisely the type of evidence FDA is willing to accept from one strong study. ⸻ 3) Less regulatory complexity than classic cancer medicine Compared to classic oncology treatment (such as with Curasight’s uTREAT): • FluoGuide does not have to prove overall survival benefit (OS) initially • the focus is on surgical outcome and visualization ➡️ This makes it more likely that FDA will accept one pivotal study. ⸻ 📊 What does this mean for the investment case? 💰 Capital requirements • One study instead of two can save very large amounts • increases the likelihood of reaching goals without massive capital raising 🤝 Partnering/M&A Big Pharma / MedTech may be more interested when: • there is a short path to approval • and low regulatory risk 👉 Increases the chance of a licensing agreement or acquisition earlier in the process 📈 Valuation The market usually rewards: • shorter timelines • higher probability of approval • lower cash burn ⸻ 🇪🇺 EU perspective Although approval in the EU goes via the European Medicines Agency: • The study will typically be designed so that it can be used for both FDA and EMA • EMA may require: • extra data • or an expanded cohort But: 👉 if FDA accepts one strong study, the probability of EU approval on the same data basis increases ⸻ ⚠️ What are still risks? Even with the new FDA line: • One study = binary risk • FDA may still require: • extra safety data • imaging quality data • If endpoints are not clear → they may still require an additional study ⸻ 🧾 Bottom line for FluoGuide 👉 The new FDA standard is very positive for FluoGuide In practice, this means: • faster path to market • lower capital requirements • better partnering opportunities • higher strategic value ➡️ Among Danish small-cap biotechs, FluoGuide is one of those that benefits most directly from this regulatory change.·3 päivää sittenWhy does that result in lower capital requirements? I think it increases the capital requirement and know-how initially, and any potential savings can only be realized back-end upon success. All else being equal, it thus increases investors' risk appetite in the initial phase, and then there will be a payback if it succeeds. If it doesn't succeed, the loss will be greater because a large study was initiated earlier than otherwise. Why should that provide a better partner opportunity? It would rather imply that it increases the requirement to bring in a large partner as an investor, and thus one would have to sell out earlier in the journey, whereas one often sees a large return by taking phase 2 on one's own and waiting for a partnership until phase 3. Higher strategic value? Can that expression be translated into something that makes sense?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
689
Myynti
Määrä
705
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 56 | - | - | ||
| 500 | - | - | ||
| 60 | - | - | ||
| 91 | - | - |
Ylin
35,5VWAP
Alin
34,3VaihtoMäärä
0,1 1 757
VWAP
Ylin
35,5Alin
34,3VaihtoMäärä
0,1 1 757
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 757 | 1 757 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 757 | 1 757 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
1 päivä sitten
‧24 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·20.2.Ding Dong. FDA clears FluoGuides IND for FG001 🙌 https://storage.mfn.se/139b3b18-5b33-44a9-ad66-87fb5655209a/fda-clears-fluoguides-ind-for-fg001-in-high-grade-glioma-u-s-clinical-trial-remains-on-track.pdf
- ·19.2.The direct effect of FDA's new practice See the attached image . 1) One pivotal study may be enough → big gain The new FDA standard means that FluoGuide can potentially: 👉 Pursue one large registration study instead of two Consequences: • 🕒 Shorter path to market (1–3 years faster) • 💰 Lower development costs • 📉 Less capital raising / less dilution For a small Danish biotech company, this is very valuable. ⸻ 2) Endpoints fit well with the “one trial” model FluoGuide's type of product actually lends itself quite well to a one-study setup, because: • the effect can be measured directly during surgery (e.g.: more complete resections, fewer positive margins) • strong, objective endpoints can be obtained • results can often be seen quickly 👉 This is precisely the type of evidence FDA is willing to accept from one strong study. ⸻ 3) Less regulatory complexity than classic cancer medicine Compared to classic oncology treatment (such as with Curasight’s uTREAT): • FluoGuide does not have to prove overall survival benefit (OS) initially • the focus is on surgical outcome and visualization ➡️ This makes it more likely that FDA will accept one pivotal study. ⸻ 📊 What does this mean for the investment case? 💰 Capital requirements • One study instead of two can save very large amounts • increases the likelihood of reaching goals without massive capital raising 🤝 Partnering/M&A Big Pharma / MedTech may be more interested when: • there is a short path to approval • and low regulatory risk 👉 Increases the chance of a licensing agreement or acquisition earlier in the process 📈 Valuation The market usually rewards: • shorter timelines • higher probability of approval • lower cash burn ⸻ 🇪🇺 EU perspective Although approval in the EU goes via the European Medicines Agency: • The study will typically be designed so that it can be used for both FDA and EMA • EMA may require: • extra data • or an expanded cohort But: 👉 if FDA accepts one strong study, the probability of EU approval on the same data basis increases ⸻ ⚠️ What are still risks? Even with the new FDA line: • One study = binary risk • FDA may still require: • extra safety data • imaging quality data • If endpoints are not clear → they may still require an additional study ⸻ 🧾 Bottom line for FluoGuide 👉 The new FDA standard is very positive for FluoGuide In practice, this means: • faster path to market • lower capital requirements • better partnering opportunities • higher strategic value ➡️ Among Danish small-cap biotechs, FluoGuide is one of those that benefits most directly from this regulatory change.·3 päivää sittenWhy does that result in lower capital requirements? I think it increases the capital requirement and know-how initially, and any potential savings can only be realized back-end upon success. All else being equal, it thus increases investors' risk appetite in the initial phase, and then there will be a payback if it succeeds. If it doesn't succeed, the loss will be greater because a large study was initiated earlier than otherwise. Why should that provide a better partner opportunity? It would rather imply that it increases the requirement to bring in a large partner as an investor, and thus one would have to sell out earlier in the journey, whereas one often sees a large return by taking phase 2 on one's own and waiting for a partnership until phase 3. Higher strategic value? Can that expression be translated into something that makes sense?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
689
Myynti
Määrä
705
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 56 | - | - | ||
| 500 | - | - | ||
| 60 | - | - | ||
| 91 | - | - |
Ylin
35,5VWAP
Alin
34,3VaihtoMäärä
0,1 1 757
VWAP
Ylin
35,5Alin
34,3VaihtoMäärä
0,1 1 757
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 757 | 1 757 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 757 | 1 757 | 0 | 0 |